Synthesis and Antiviral Activity of 2-Substituted Analogs of Triciribine

Nucleosides, Nucleotides and Nucleic Acids

Volumn 22, Issue 12, 2003, Pages 2171-2193

  Porcari, Anthony R ^a,c   Ptak, Roger G ^a,b   Borysko, Katherine Z ^a   Breitenbach, Julie M ^a   Drach, John C ^a   Townsend, Leroy B ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

Author keywords

2 Substituted analogs; HCMV; HIV; HSV 1; Pyrrolo 2,3 d pyrimidine nucleosides; Triciribine; Triciribine monophosphate

Indexed keywords

2 CHLOROTRICIRIBINE; 2 ETHYLTRICIRIBINE; 2 METHYLTRICIRIBINE; 2 PHENYLTRICIRIBINE; ANTIVIRUS AGENT; DRUG METABOLITE; TRICIRIBINE; TRICIRIBINE PHOSPHATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRICAL PARAMETERS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; NONHUMAN; PHOSPHORYLATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ACENAPHTHENES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; CYTOMEGALOVIRUS; HERPESVIRUS 1, HUMAN; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; KB CELLS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; PURINE NUCLEOSIDES; RIBONUCLEOSIDES; RIBONUCLEOTIDES;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMPLEXVIRUS;

EID: 0346220224     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-120026873     Document Type: Article

References (49)

1. Schram, K.H.; Townsend, L.B. The synthesis of 6-amino-4-methyl-8-(β -D-ribofuranosyl)(4-H, 8-H)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine, a new tricyclic nucleoside. Tetrahedron Lett. 1971, 49, 4757-4760.
2. Townsend, L.B.; Lewis, A.F.; Roti Roti, L.W. Synthesis of 6-Amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c] pyridazine-5′-phosphate as a Novel Compound and Its Utility Against L-1210 Mouse Leukemia. US Patent 4, 123, 524, October 31, 1978.
3. Plagemann, P.G. Transport, phosphorylation, and toxicity of a tricyclic nucleoside in cultured Novikoff rat hepatoma cells and other cell lines and release of its monophosphate by the cells. J. Natl. Cancer Inst. 1976, 57, 1283-1295.
4. Roti Roti, L.W.; Roti Roti, J.L.; Townsend, L.B. Studies on the mechanism of cytotoxicity of tricyclic nucleoside NSC#154020 in L1210 cells. Proc. Am. Assoc. Cancer Res. 1978, 19, 40.
5. Bennett, L.L., Jr.; Smithers, D.; Hill, D.L.; Rose, L.M.; Alexander, J.A. Biochemical properties of the nucleoside of 3-amino-1,5-dihydro-5-methyl-1,4,5,6,8-pentaazaacenaphthylene (NSC-154020). Biochem. Pharmacol. 1978, 27, 233-241.
6. Schweinsberg, P.D.; Smith, R.G.; Loo, T.L. Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem. Pharmacol. 1981, 30, 2521-2526.
7. Wotring, L.L.; Townsend, L.B.; Crabtree, G.W.; Parks, R.E., Jr. A possible role for ecto-5′-nucleotidase in cytotoxicity and intracellular nucleotide formation from the tricyclic nucleoside-5′-phosphate (TCN-P). Proc. Am. Assoc. Cancer Res. 1981, 22, 257.
8. Bennett, L.L., Jr.; Allan, P.W.; Chang, C.H. Phosphorylation of "tricyclic nucleoside" by adenosine kinases from L1210 cells and HEp-2 cells. Biochem. Pharmacol. 1983, 32, 2601-2602.
9. Wotring, L.L.; Passiatore, J.E.; Roti Roti, J.L.; Hudson, J.L.; Townsend, L.B. Effects of the tricyclic nucleoside 6-amino-4-methyl-8-(β-D- ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine on the viability and cell cycle distribution of L1210 cells in vitro. Cancer Res. 1985, 45, 6355-6361.
10. Moore, E.C.; Hurlbert, J.M.; Ravel, J.M.; Massia, S. Mechanisms of inhibition of protein and purine biosynthesis by tricyclic nucleoside phosphate (TCN-P, triciribine phosphate, NSC 280594). Proc. Am. Assoc. Cancer Res. 1986, 27, 303.
11. Behrens, B.C.; Hamilton, T.C.; Louie, K.G.; Grotzinger, K.R.; McKoy, W.M.; Tsuruo, T.; Young, R.C.; Ozols, R.F. Activity of tricyclic nucleoside 5′-phosphate in model systems of human ovarian cancer. Invest. New Drugs 1986, 4, 295-304.
12. Wotring, L.L.; Crabtree, G.W.; Edwards, N.L.; Parks, R.E., Jr.; Townsend, L.B. Mechanism of activation of triciribine phosphate (TCN-P) as a prodrug form of TCN. Cancer Treat Rep. 1986, 70, 491-497.
13. Wotring, L.L.; Roti Roti, J.L.; Hudson, J.L.; Passiatore, J.E.; Borysko, K.Z.; Newcomb, R.D.; Townsend, L.B. Triciribine (TCN), a novel tricyclic adenosine analog with anticancer activity. Nucleosides Nucleotides 1987, 6, 95-109.
14. Wotring, L.L.; Townsend, L.B.; Mandell, K.L.; Borysko, K.Z. Metabolism of triciribine in L1210 cells. Proc. Am. Assoc. Cancer Res. 1989, 30, 590.
15. Moore, E.C.; Hurlbert, R.B.; Boss, G.R.; Massia, S.P. Inhibition of two enzymes in de novo purine nucleotide synthesis by triciribine phosphate (TCN-P). Biochem. Pharmacol. 1989, 38, 4045-4051.
16. Wotring, L.L.; Townsend, L.B.; Jones, L.M.; Borysko, K.Z.; Gildersleeve, D.L.; Parker, W.B. Dual mechanisms of inhibition of DNA synthesis by triciribine. Cancer Res. 1990, 50, 4891-4899.
17. Moore, E.C.; Hurlbert, R.B.; Massia, S.P. Inhibition of CCRF-CEM human leukemic lymphoblasts by triciribine (tricyclic nucleoside, TCN, NSC-154020). Accumulation of drug in cells and comparison of effects on viability, protein synthesis and purine synthesis. Biochem. Pharmacol. 1989, 38, 4037-4044.
18. Basseches, P.J.; Durski, A.; Powis, G. High-performance liquid chromatographic assay of the antineoplastic agent tricyclic nucleoside 5′-phosphate and its disposition in rabbit. J. Chromatogr. 1982, 233, 227-234.
19. Basseches, P.J.; Powis, G. Metabolism and disposition of 3-amino-1,5-dihydro-5-methyl-1-β-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene in the rat. Cancer Res. 1984, 44, 3672-3678.
20. Liu, C.; Kimler, B.F.; Evans, R.G.; Morantz, R.A. Intracerebral chemotherapy in the 9L rat brain tumor model. Proc. Ann. Meet. Am. Assoc. Cancer Res. 1992, 33, A2654.
21. Schilcher, R.B.; Young, J.D.; Baker, L.H. Reversed-phase high-performance liquid chromatographic determination of tricyclic nucleoside and tricyclic nucleoside 5′-phosphate in biological specimens. J. Chromatogr. 1985, 337, 55-62.
22. Townsend, L.B.; Milne, G.H. Synthesis, chemical reactivity, and chemotherapeutic activity of certain selenonucleosides and nucleosides related to the pyrrolo[2,3-d]-pyrimidine nucleoside antibiotics. Ann. N.Y. Acad. Sci. 1975, 255, 91-103.
23. Mittelman, A.; Casper, E.S.; Godwin, T.A.; Cassidy, C.; Young, C.W. Phase I study of tricyclic nucleoside phosphate. Cancer Treat Rep. 1983, 67, 159-162.
24. Cobb, W.R.; Bogden, A.E.; Reich, S.D.; Griffin, T.W.; Kelton, D.E.; LePage, D.J. Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay. Cancer Treat. Rep. 1983, 67, 173-178.
25. Crabtree, G.W.; Spremulli, E.N.; Weiman, M.C.; Smith, D.E.; Salvatore, J.R.; Cummings, F.J.; Calabresi, P. Phase I clinical and pharmacokinetic study of tricyclic nucleoside 5′-monophosphate (TCN-P; NSC 280594). Proc. Am. Soc. Clin. Oncol. 1983, 2, 33.
26. Feun, L.G.; Savaraj, N.; Bodey, G.P.; Lu, K.; Yap, B.S.; Ajani, J.A.; Burgess, M.A.; Benjamin, R.S.; McKelvey, E.; Krakoff, I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 1984, 44, 3608-3612.
27. Powis, G.; Basseches, P.J.; Kroschel, D.M.; Richardson, R.L.; O'Connell, M.J.; Kvols, L.K. Disposition of tricyclic nucleoside-5′-monophosphate in blood and plasma of patients during phase I and II clinical trials. Cancer Treat Rep. 1986, 70, 359-362.
28. Schilcher, R.B.; Haas, C.D.; Samson, M.K.; Young, J.D.; Baker, L.H. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5′-phosphate using a weekly intravenous regimen. Cancer Res. 1986, 46, 3147-3151.
29. Hoffman, K.; Holmes, F.A.; Fraschini, G.; Esparza, L.; Frye, D.; Raber, M.N.; Newman, R.A.; Hortobagyi, G.N. Phase I-II study: Triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother. Pharmacol. 1996, 37, 254-258.
30. O'Connell, M.J.; Rubin, J.; Hahn, R.G.; Kvols, L.K.; Moertel, C.G. Phase II clinical trial of tricyclic nucleoside phosphate for advanced colorectal cancer. Cancer Treat Rep. 1987, 71, 333-334.
31. Lyss, A.P.; Morrell, L.E.; Perry, M.C. Triciribine phosphate (TCN-P) in advanced non-small cell lung cancer (NSCLC): Interim analysis of toxicity. Proc. Am. Soc. Clin. Oncol. 1991, 10, 120.
32. Feun, L.G.; Blessing, J.A.; Barrett, R.J.; Hanjani, P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A gynecologic oncology group study Am. J. Clin. Oncol. 1993, 16, 506-508.
33. Kucera, L.S.; Iyer, N.P.; Puckett, S.H.; Buckheit, R.W., Jr.; Westbrook, L.; Toyer, B.R.; White, E.L.; Germany-Decker, J.M.; Shannon, W.M.; Chen, R.C.; Nassiri, M.R.; Shipman, C., Jr.; Townsend, L.B.; Drach, J.C. Activity of triciribine and triciribine-5′-monophosphate against human immunodeficiency virus types 1 and 2. AIDS Res. Hum. Retroviruses 1993, 9, 307-314.
34. Ptak, R.G.; Borysko, K.Z.; Porcari, A.R.; Buthod, J.L.; Holland, L.E.; Shipman, C., Jr.; Townsend, L.B.; Drach, J.C. Phosphorylation of triciribine is necessary for activity against HIV-1. AIDS Res. Human Retroviruses 1998, 14, 1315-1322.
35. Townsend, L.B.; Kawasaki, A.M.; VanSickle, A.P.; Wotring, L.L. The synthesis and biological activity of certain pentaazaacenaphthylenes, hexaazaacenaphthylenes and their corresponding nucleosides. Nucleic Acids Symp. Ser. 1986, 17, 41-44.
36. Kawasaki, A.M.; Townsend, L.B. An unusual reductive ring-opening of the 1,2,3,5,6,7-hexaazaacenaphthylene ring system. Tetrahedron Lett. 1989, 30, 3287-3290.
37. VanSickle, A.; Kawasaki, A.M.; Townsend, L.B. The Synthesis of 8-amino-6-N-methyl-1,2,3,5,6,7-hexaazaacenaphthylene. Heterocycles 1990, 30, 963-969.
38. Kawasaki, A.M.; Wotring, L.L.; Townsend, L.B. Synthesis and cytotoxicity studies of 8-amino-6-methyl-2-β -D-ribofuranosyl-1,2,3,5,6,7-hexaazaacenaphthylene (7-aza-TCN) and the corresponding 2′-deoxy- and arabinonucleoside analogues. J. Med. Chem. 1990, 33, 3170-3176.
39. Kawasaki, A.M.; Townsend, L.B. Synthesis of 8-amino-4-methylthio-6-methyl-2-(β-D-ribofuranosyl)-2,6-dihydro-1,2,3,5,6, 7-hexaazaacenaphthylene and an unusual reductive ring-opening of the 1,2,3,5,6,7-hexaazaacenaphthylene ring system. J. Heterocycl. Chem. 1991, 28, 1-5.
40. Porcari, A.R.; Borysko, K.Z.; Ptak, R.G.; Breitenbach, J.M.; Wotring, L.L.; Drach, J.C.; Townsend, L.B. Acyclic sugar analogs of triciribine: Correlation of antiviral and antineoplastic activity with intracellular phosphorylation. Nucleosides & Nucleotides 1999, 18, 2475-2497.
41. Porcari, A.R.; Borysko, K.Z.; Ptak, R.G.; Breitenbach, J.M.; Vittori, S. ; Wotring, L.L.; Drach, J.C.; Townsend, L.B. Deoxy sugar analogs of triciribine: Correlation of antiviral and antineoplastic activity with intracellular phosphorylation. J. Med. Chem. 2000, 43, 2438-2448.
42. Swayze, E.E.; Hinkley, J.M.; Townsend, L.B. The improved preparation of a versatile synthon for the synthesis of pyrrolo[2,3-d]pyrimidines. In Nucleic Acid Chemistry; Townsend, L.B., Tipson, R.S., Eds.; Wiley-Interscience: New York, 1991; Vol. 4, 16-17.
43. 0. J. Am. Chem. Soc. 1976, 98, 7870-7872.
44. Turk, S.R.; Shipman, C., Jr.; Nassiri, M.R.; Genzlinger, G.; Krawczyk, S.H.; Townsend, L.B.; Drach, J.C. Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 1987, 31, 544-550.
45. Kucera, L.S.; Iyer, N.; Leake, E.; Raben, A.; Modest, E.J.; Daniel, L.W. ; Piantadosi, C. Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Res. Hum. Retroviruses 1990, 6, 491-501.
46. White, E.L.; Buckheit, R.W.; Ross, L.J.; Germany, J.M.; Andries, K.; Pauwels, R.; Janssen, P.A.J.; Shannon, W.M.; Chirigos, M.A. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991, 16, 257-266.
47. Prichard, M.N.; Shipman, C., Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14, 181-205.
48. Prichard, M.N.; Prichard, L.E.; Baguley, W.A.; Nassiri, M.R.; Shipman, C., Jr. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Antimicrob. Agents Chemother. 1991, 35, 1060-1065.
49. Walseth, T.F.; Graff, G.; Moos, M.C., Jr.; Goldberg, N.D. Separation of 5′-ribonucleoside monophosphates by ion-pair reverse-phase high-performance liquid chromatography. Analytical Biochemistry 1980, 107 (1), 240-245.